Tempus AI Investors May Lead Securities Fraud Lawsuit, Deadline to Participate is August 12, 2025.
PorAinvest
miércoles, 16 de julio de 2025, 4:04 pm ET1 min de lectura
AZN--
Tempus AI investors who have suffered significant losses have an opportunity to participate in a securities fraud class action lawsuit. The lawsuit, filed by the Law Offices of Howard G. Smith, alleges that Tempus AI, Inc. (NASDAQ: TEM) and its officers violated federal securities laws by failing to disclose critical information to investors [1].
The class action lawsuit, which was filed on July 15, 2025, seeks to recover damages on behalf of investors who purchased Tempus securities between August 6, 2024, and May 27, 2025, inclusive [1]. The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded. Additionally, it is claimed that the joint venture with SoftBank was at risk due to the appearance of "round-tripping" capital to create revenue for Tempus [1].
Furthermore, the lawsuit alleges that Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability. AstraZeneca, too, had reduced its financial commitments to Tempus through a questionable "pass-through payment" via a joint agreement with Pathos AI [1].
These issues, according to the complaint, revealed weaknesses in Tempus's core operations and revenue prospects, making the company's positive statements about its business, operations, and prospects materially false and misleading [1]. The price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025 [1].
Investors who wish to participate in the class action lawsuit should contact the Law Offices of Howard G. Smith before the lead plaintiff deadline of August 12, 2025 [2]. There is no cost to investors, as the law firm represents investors in class actions on a contingency fee basis [2].
References
[1] https://www.morningstar.com/news/globe-newswire/9491245/tem-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-tempus-ai-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit
[2] https://www.prnewswire.com/news-releases/tempus-ai-inc-tem-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302507021.html
TEM--
Tempus AI investors who suffered losses can lead a securities fraud class action lawsuit. The complaint alleges that the company inflated the value of contract agreements, engaged in questionable billing practices, and misrepresented its business operations. Investors have until August 12, 2025, to participate in the ongoing lawsuit. Contact the Law Offices of Howard G. Smith for more information.
Title: Tempus AI Investors Can Lead Securities Fraud Class Action LawsuitTempus AI investors who have suffered significant losses have an opportunity to participate in a securities fraud class action lawsuit. The lawsuit, filed by the Law Offices of Howard G. Smith, alleges that Tempus AI, Inc. (NASDAQ: TEM) and its officers violated federal securities laws by failing to disclose critical information to investors [1].
The class action lawsuit, which was filed on July 15, 2025, seeks to recover damages on behalf of investors who purchased Tempus securities between August 6, 2024, and May 27, 2025, inclusive [1]. The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded. Additionally, it is claimed that the joint venture with SoftBank was at risk due to the appearance of "round-tripping" capital to create revenue for Tempus [1].
Furthermore, the lawsuit alleges that Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability. AstraZeneca, too, had reduced its financial commitments to Tempus through a questionable "pass-through payment" via a joint agreement with Pathos AI [1].
These issues, according to the complaint, revealed weaknesses in Tempus's core operations and revenue prospects, making the company's positive statements about its business, operations, and prospects materially false and misleading [1]. The price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025 [1].
Investors who wish to participate in the class action lawsuit should contact the Law Offices of Howard G. Smith before the lead plaintiff deadline of August 12, 2025 [2]. There is no cost to investors, as the law firm represents investors in class actions on a contingency fee basis [2].
References
[1] https://www.morningstar.com/news/globe-newswire/9491245/tem-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-tempus-ai-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit
[2] https://www.prnewswire.com/news-releases/tempus-ai-inc-tem-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302507021.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios